Otsuka : Notice Regarding Company Split (Simplified Absorption–type Company Split) (212KB)

For Immediate Release

November 14, 2017

Company name	Otsuka Holdings Co., Ltd.
Representative	Tatsuo Higuchi President and Representative Director, CEO
Code number	4578 First Section , Tokyo Stock Exchange
Inquiries	Yuji Kogure Director, Investors Relations Department

Notice Regarding Company Split (Simplified Absorption-type Company Split)

Otsuka Holdings Co., Ltd. ("the Company") announces that it has resolved at the meeting of its Board of Directors held today to transfer its assets related to renal denervation ("the Company Split") to Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices"), a fully-owned subsidiary of the Company.

Certain information has been omitted from this announcement since the Company Split is a simplified absorption-type company split in which the Company will transfer the assets to its wholly owned consolidated subsidiary.

1. Purpose of the Company Split

   The Company, in 2014, invested in ReCor Medical Inc. and its ultrasound renal denervation technology developed in the United States for treatment of hypertension (the "Business"). On May 16, 2016, the Company obtained exclusive rights to the commercialization of the Business in Japan, China, Korea and other Asian countries. (Reference: "Otsuka Holdings Announces Collaboration with ReCor Medical for Commercialization of ReCor Medical's Ultrasound Renal Denervation Technology in Asia" https://www.otsuka.com/en/hd_release/release/pdf.php?news=1338 )

   In order to optimize the allocation of group resources and to so further strengthen the group's business platform, the board has decided that the Business will be transferred to and continued to be managed by Otsuka Medical Devices, a fully-owned subsidiary of the Company primarily oversees medical device operations within the Otsuka group of companies.

2. Outline of the Company Split

3. Schedule

   November 10, 2017 Resolution by the Board of Directors of Otsuka Medical Devices November 13, 2017 Resolution by the shareholders meeting of Otsuka Medical Devices November 14, 2017 Resolution by the Board of Directors of the Company

   November 14, 2017 Company Split Agreement to be executed by the Company and Otsuka Medical Devices

   January 1, 2018 Effective date of the Company Split

   Note: Since the Company Split satisfied the requirement for a simplified company split stipulated in Article 784 (2) of the Companies Act, the Company as the splitting company does not require and will not request the approval by a shareholders meeting.

4. Method of Company Split

   This is an absorption-type company split (simplified company split) in which the Company is the splitting company and Otsuka Medical Devices is the successor company.

5. Details of Allotments Related to the Company Split

   The successor company will issue 80,000 shares of common stock and allot them to the Company.

6. Handling of Stock Acquisition Rights and Bonds with Stock Acquisition Rights Accompanying the Company Split The Company issues no stock acquisition rights and no bonds with stock acquisition rights.

7. Deduction of Capital due to the Company Split

   There is no increase or decrease in capital related to the Company Split.

8. Rights and Obligations to be Assumed by Successor Company

   For the purpose of the Company Split, the successor company will assume all assets considered necessary for conducting the Business.

9. Prospect of Fulfillment of Obligations

10. The Company considers there to be no problem relating to the prospect of fulfillment of obligation to be borne by the Company or the successor company for the purpose of the Company Split.

11. Summary of Companies Involved in the Company Split

12. Splitting Company ( As of December 31, 2016)	Successor Company ( As of December 31, 2016)
    (1) Company Name	Otsuka Holdings Co., Ltd.	Otsuka Medical Devices Co., Ltd.
    (2) Head Office	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan
    (3) Representative	Tatsuo Higuchi President and Representative Director, CEO	Noriko Tojo President and Representative Director
    (4) Summary of Business	Control, management and related activities with respect to the Company's subsidiaries and affiliates active in the pharmaceutical industry, nutraceutical industry, consumer products, and other areas.	Overseeing medical device operations within the Otsuka group and the business activities of companies engaged in related businesses, as well as all operations related to the foregoing activities.
    (5) Paid-in Capital	¥ 81.69 billion	¥ 4.8billion
    (6) Establishment	July 8, 2008	February 15, 2011
    (7) Number of Shares Issued	557,835,617shares	222,000 shares
    (8) Book Closing Date	December 31	December 31
    (9) Principal Shareholders and Shareholding Ratio	The Nomura Trust & Banking Co. Japan Trustee Services Bank, Ltd. (Trust Account) 10.78% Otsuka Estate Limited 4.10% The Master Trust Bank of Japan, Co., Ltd. (Trust Account) 3.05% Otsuka Group Employee Shareholding Fund 2.53% Otsuka Founders Shareholding Fund Trust Account 11.22%	- Otsuka Holdings Co., Ltd. 100%

    (10) Operating Results for the Most Recent Business Year and Financial Positions as of the End of the Business Year (In millions of yen, except for those stated otherwise)
    Name	Otsuka Holdings Co., Ltd. (consolidated)	Otsuka Medical Devices Co., Ltd.
    Fiscal Year	Ended December 31, 2016	Ended December 31, 2016
    Total Equity (Equity attributable to owners of the Company)	1,710,531	10,744
    Total Assets	2,478,290	16,563
    Equity Attributable to owners of the Company per Share (yen)	3,156.83	48,396.08
    Net Sales	1,195,547	10
    Operating Profit	101,145	▲483
    Ordinary Income	－	▲551
    Profit Attributable to owners of the Company	92,563	▲206
    Basic Earnings per Share (yen)	170.82	▲929.08

13. Outline of the Business Section Subject to the Company Split

14. Outline of the Business

    Medical device system utilizing ultrasound renal denervation technology

15. Operating Results of the Business Section Subject to the Company Split

    There are no operating results of the Business in Asia, where the Company has exclusive rights to the commercialization, as the technology concerned is still in clinical development.

16. Assets and Liabilities To be Split Off (scheduled) (millions of yen)

17. Assets		Liabilities
    Current assets	70	Current liabilities	-
    Non-current assets	4,484	Non-current liabilities	-
    Total	4,555	Total	-

18. Status of the Company after the Company Split

    There will be no change in the trade name, location of the head office, name and title of the representative, line of business, paid-in capital or accounting term due to the Company Split.

19. Future Outlook

20. The Company Split is expected to have only minor impacts on the consolidated business results of the Company because it is a transaction between the Company and a wholly owned subsidiary.